Curevac N V's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Curevac N V (CVAC) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Curevac N V vs Its Competitors
- TTM: Trailing 12-month revenue of 599M vs 169,791M combined for tracked competitors (0.4% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months), vs accelerating (+65.1%) for its tracked peer group.
- Growth: Curevac N V generated 895.5% revenue growth year over year in Q4 2024, vs 88.1% for its tracked competitors combined.
- Profitability: Its -6.9% net margin compares with 2.4% for the peer group.
- Peer revenue share: Curevac N V accounted for 0.9% of combined revenue among its tracked peer group, up from 0.2% a year earlier.
- Peer differentiation: Revenue per employee of $1.62M compares with $1.18M for the peer group (1.4x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
CVAC Sales vs. its Competitors, Q4 2024
Curevac N V reported revenue growth of 895.54 % year on year in Q4 2024, above its competitors' combined revenue growth of 88.05 %.
With a net margin of -6.88 %, Curevac N V reported lower profitability than its competitors (2.35 %).
Curevac N V generated 0.85 % of the combined sales of its peer group, up from 0.16 % a year earlier.
Curevac N V vs. its Competitors, Q4 2024
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Curevac N V and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Curevac N v | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (2) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Curevac N V's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 7.2% year over year, combined, vs 895.5% for Curevac N V. Curevac N V's share of combined industry revenue moved from 0.01% to 0.08%, a gain of 0.07 percentage points.
Curevac N V's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Curevac N v | - | - | - | - |
| Competitors combined (70) | ||||
| High-Confidence Competitors (3) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
CVAC Stock Performance relative to its Competitors
CVAC Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Moderna Inc | 282.9% | Outperformed |
| 2 | An2 Therapeutics Inc | 282.9% | Outperformed |
| 3 | 180 Life Sciences Corp | 282.9% | Outperformed |
| 4 | Immunome Inc | 282.9% | Outperformed |
| 5 | Arcus Biosciences Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Curevac N V's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Curevac N v
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Curevac N v | 1,049.76 | 599.40 |
| Pfizer Inc | 162,677.96 | 63,696.00 |
| Bristol myers Squibb Company | 128,634.88 | 49,186.00 |
| Gsk Plc | 101,339.75 | 32,667.00 |
| Regeneron Pharmaceuticals Inc | 80,401.00 | 15,534.70 |
| Moderna Inc | 76,517.49 | 2,228.00 |
| SUBTOTAL | 637,514.27 | 170,521.36 |
Sign in to see all competitors of Curevac N v .
Sources: Curevac N v's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Curevac N v versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Curevac N V's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Pfizer | Named by the company | 85% |
| BioNTech | Named by the company | 85% |
| Immutep Limited | Named by the company | 85% |
| Frame Cancer Therapeutics | Named by the company | 85% |
| Telesis Bio Inc | Named by the company | 85% |
| Ocugen Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Curevac N V's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Curevac N V's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Curevac N v | 1,050 | 1,620,004 | 490,941 |
| Pfizer Inc | 162,678 | 849,280 | 58,267 |
| Bristol myers Squibb Company | 128,635 | 1,513,415 | 285,354 |
| Gsk Plc | 101,340 | 128,610,236 | 24,759,843 |
| Regeneron Pharmaceuticals Inc | 80,401 | 1,008,092 | 280,902 |
| Moderna Inc | 76,517 | 474,043 | -670,426 |
| PEERS TOTAL | 636,465 | 1,177,838 | 95,787 |
Curevac N V's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Pfizer Inc | United States 58.91 % |
| Bristol myers Squibb Company | United States 67.79 % |
| Novavax inc | United States 68.88 % |
| Opko Health Inc | US 54.29 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Curevac N V's Business Segment Mix vs Peers
Revenue by operating segment, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Pfizer Inc | U.S. Commercial Division 52.92 % |
| Arcus Biosciences Inc | Reportable 100.00 % |
| Immunome Inc | Single reportable segment 100.00 % |
| Novavax inc | Reportable 100.00 % |
| Emergent Biosolutions Inc | MCM Products 65.21 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Curevac N V's Position in Industry Market Structure
Market-capitalization share and concentration across all 498 companies in Curevac N V's industry classification, broader than the peer set above. Market cap in millions of $.Curevac N V ranks #0 of 498 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 827, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,062,533 | 19.39 % |
| 2 | Johnson and Johnson | 664,610 | 12.13 % |
| 3 | Beone Medicines Ltd | 545,679 | 9.96 % |
| 4 | Abbvie Inc | 467,633 | 8.54 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 0 | Curevac N v | 1,176 | 0.00 % |
Market cap and industry share for the rest of Curevac N V's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-01-05.
Curevac N V's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 827 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Curevac N V's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Curevac N V's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Curevac N V's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) — not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months).
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
No rule matched.
Opportunities
- A meaningful share of tracked competitors (43.80 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Curevac N V's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Curevac N v | 6.66 | 7.28 | - |
| Pfizer Inc | 0.04 | 1.24 | 0.71 |
| Bristol myers Squibb Company | 0.49 | 1.35 | 2.31 |
| Gsk Plc | - | - | - |
| Regeneron Pharmaceuticals Inc | 0.57 | 3.74 | 0.06 |
| Moderna Inc | 0.86 | 2.88 | 0.07 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Curevac N V's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Curevac N v | Q4 2024 | +895.5 % | - |
| Pfizer Inc | Q2 2026 | +2.6 % | - |
| Bristol myers Squibb Company | Q2 2026 | +5.7 % | +152.6 % |
| Gsk Plc | Q4 2025 | +4.1 % | +113.1 % |
| Regeneron Pharmaceuticals Inc | Q2 2026 | +16.7 % | -6.8 % |
| Moderna Inc | Q2 2026 | +2.1 % | - |
| PEERS TOTAL | +5.2 % | +25.4 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Curevac N V's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Curevac N v | Q4 2024 | -14.9 % | -72.6 % |
| Pfizer Inc | Q2 2026 | +8.3 % | -13.8 % |
| Bristol myers Squibb Company | Q2 2026 | +10.5 % | -15.5 % |
| Gsk Plc | Q4 2025 | +2.9 % | -0.6 % |
| Regeneron Pharmaceuticals Inc | Q2 2026 | +109.2 % | +9.7 % |
| Moderna Inc | Q2 2026 | -21.8 % | +1,133.3 % |
Curevac N V's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Curevac N v | 20.20% | 19.86% | 23.28% |
| Pfizer Inc | 2.12% | 2.53% | 4.91% |
| Bristol myers Squibb Company | 10.27% | 13.58% | 46.65% |
| Gsk Plc | 10.29% | 51.22% | 39.41% |
| Regeneron Pharmaceuticals Inc | 10.60% | 11.83% | 13.81% |
| Moderna Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Curevac N V's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Curevac N v | 6.47 | 1.75 |
| Pfizer Inc | 37.43 | 2.55 |
| Bristol myers Squibb Company | 13.83 | 2.62 |
| Gsk Plc | 17.73 | 3.10 |
| Regeneron Pharmaceuticals Inc | 18.78 | 5.18 |
| Moderna Inc | - | 34.34 |
| PEERS AVERAGE | 45.54 | 3.74 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.